(Source: Actelion Ltd) Selexipag significantly reduced the risk of a morbidity/mortality event by 40% versus placebo (p Selexipag improved long-term outcomes in an investigational trial of patients already treated with ERA and PDE-5i combination therapy, with ERA or PDE-5i monotherapy and in treatment-naïve patients ALLSCHWIL, SWITZERLAND - 15 March 2015 - Actelion Ltd (SIX: ATLN) today announced that key long-term outcome data from the pivotal selexipag (Uptravi®) Phase III GRIPHON study were shared during an oral presentation at the American College of Cardiology (ACC) Congress in San Diego, US. The presentation highlighted that the investigational drug selexipag significantly reduced the...
↧